An FDA-cleared AI tool for breast ultrasound may reduce unnecessary biopsies of benign breast lesions by about 60%.
Key Details
- 1Research presented at RSNA 2025 evaluated the Koios DS AI tool for breast ultrasound.
- 2The study involved 14 breast imaging radiologists and 271 lesions in 253 women, with 76.8% benign and 23.2% malignant lesions.
- 3The AI tool showed 60.6% specificity, assigning many benign lesions to lower BI-RADS categories, and a sensitivity of 90.5%.
- 4The tool misclassified 6 malignant lesions, most of which had other imaging correlates.
- 5Experts emphasized the AI should be used as an adjunct, not a replacement, to radiologist judgment for biopsy decisions.
Why It Matters
Reducing unnecessary biopsies can lower patient anxiety, cut healthcare costs, and ease operational burdens on imaging practices. Integrating AI as a decision-support tool alongside radiologists could lead to more accurate, efficient, and patient-centered breast imaging workflows.
Source
AuntMinnie
Related News
•Radiology Business
a2z Radiology Raises $5M, Lands FDA Clearance for Multi-Condition CT AI
Boston-based a2z Radiology raised $4.5M and earned FDA clearance for its Unified Triage AI solution for abdominal and pelvic CT scans.
•AI in Healthcare
Nvidia, Amazon Drive AI Expansion Across Genomics and Radiology
Major healthcare and technology companies partner to push AI advancements in genomics, radiology, and broader healthcare.
•HealthExec
AI Drives Advances in Radiology, Genomics, and Healthcare Policy
Recent developments highlight AI's expanding role in radiology, genomics, and healthcare infrastructure.